Gilotrif (afatinib) — Medica
Non-small cell lung cancer – Epidermal Growth Factor Receptor (EGFR) mutation-positive
Initial criteria
- Patient is age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has sensitizing EGFR mutation-positive non-small cell lung cancer as detected by an approved test
Approval duration
1 year